Clinical trials: Double Incontinence

Urinary Bladder, Overactive

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

• Completed
• Age: 18 years and older
• Phase 3
• Results posted

The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active…

Trial name

TAURUS (NCT00688688)

Testing

Mirabegron, Tolterodine

Where

308 sites in United States, Australia and 28 more

Volunteers

2,792 people

Sponsor

Astellas Pharma Inc